Exhibit 10.16
SETTLEMENT AGREEMENT

I.   PARTIES

     This Settlement Agreement (“Agreement”) is entered into among the United
States of America, acting through the United States Department of Justice, Civil
Division, and the United States Attorney’s Office for the Eastern District of
Pennsylvania, the Office of Inspector General (“OIG-HHS”) of the Department of
Health and Human Services (“HHS”), TRICARE Management Activity (“TMA”) and the
United States Office of Personnel Management (“OPM”) (collectively the “United
States”); the Relators as identified in Paragraphs B through E of the Preamble
to this Agreement (“Relators”); and Eli Lilly and Company (“Eli Lilly”).
Collectively, all of the above will be referred to as “the Parties.”

II.   PREAMBLE

     As a preamble to this Agreement, the Parties agree to the following:

     A. At all relevant times, Eli Lilly, an Indiana corporation headquartered
in Indianapolis, Indiana, distributed, marketed and sold pharmaceutical products
in the United States, including a drug sold under the trade name of Zyprexa.
     The qui tam actions identified in Paragraphs (B) through (E) will be
referred to collectively as the “Civil Actions.”
     B. Robert Rudolph (“Rudolph”), Hector Rosado (“Rosado”), and Robert Evan
Daywitt (“Daywitt”) filed a qui tam action in the United States District Court
for the Eastern

-1-

--------------------------------------------------------------------------------

 

District of Pennsylvania captioned United States of America ex rel. Robert
Rudolph, et al., v. Eli Lilly and Company, Civil Action No. 03-943. On
August 13, 2003, Rudolph, Rosado and Daywitt filed a first amended complaint,
adding relators Bradley Lutz (“Lutz”) and James Wetta (“Wetta”). A second
amended complaint was filed on September 27, 2007, adding relator William Lofing
(“Lofing”).
     C. Joseph Faltaous (“Faltaous”) filed a qui tam action in the United States
District Court for the Eastern District of New York captioned United States of
America ex rel. Joseph Faltaous v. Eli Lilly and Company, Civil Action
No. 05-1471. That action was transferred to the Eastern District of Pennsylvania
as Civil Action No. 06-2909.

     D. Steven Woodward (“Woodward”) filed a qui tam action in the United States
District Court for the Eastern District of Pennsylvania captioned United States
ex rel. Steven Woodward v. Dr. George B. Jerusalem, Tesse Jerusalem, Bay
Psychiatric Services, and Eli Lilly, Civil Action No. 06-5526.
     E. Jaydeen Vicente (“Vicente”) filed a qui tam action in the United States
District Court for the Eastern District of Pennsylvania captioned United States
of America ex rel. Javdeen Vicente v. Eli Lilly and Company, Civil Action
No. 07-1791.
     F. Eli Lilly has entered into a plea agreement with the United States
Attorney for the Eastern District of Pennsylvania and the Office of Consumer
Litigation of the Department of Justice and has agreed to plead guilty, pursuant
to Fed.R.Crim.P. 11 to specific conduct described in a plea agreement to be
filed in United States v. Eli Lilly and Company (the “Federal Criminal Action”).
     G. Eli Lilly will be entering into separate settlement agreements,
described in

-2-

--------------------------------------------------------------------------------

 

Paragraph III.1(b) below (hereinafter referred to as the “Medicaid State
Settlement Agreements”) with certain states and the District of Columbia in
settlement of the Covered Conduct. States with which Eli Lilly executes a
Medicaid State Settlement Agreement in the form to which Eli Lilly and the
National Association of Medicaid Fraud Control Units (“NAMFCU”) have agreed, or
in a form otherwise agreed to by Eli Lilly and an individual State, shall be
defined as “Medicaid Participating States.”
     H. The United States and the Medicaid Participating States allege that Eli
Lilly caused claims for payment for Zyprexa to be submitted to the Medicaid
Program, Title XIX of the Social Security Act, 42 U.S.C. §§ 1396-1396v (“the
Medicaid Program”).
     I. The United States further alleges that Eli Lilly caused claims for
payment for Zyprexa to be submitted to the TRICARE program, 10 U.S.C. §§
1071-1109; the Federal Employees Health Benefits Program (“FEHBP”), 5 U.S.C. §§
8901-8914; and caused purchases of Zyprexa by the Department of Veterans Affairs
(“DVA”), the Bureau of Prisons (“BOP”), the Department of Defense, the
Department of Labor, and the Public Health Service Entities.
     J. The United States contends that it has certain civil claims against Eli
Lilly, as specified in Paragraph III.2 below, for engaging in the following
conduct concerning the marketing, promotion and sale of Zyprexa between
September 1999 and December 31, 2005 (hereinafter referred to as the “Covered
Conduct”):

-3-

--------------------------------------------------------------------------------

 

         
 
  Eli Lilly knowingly promoted the sale and use of Zyprexa to psychiatrists,
other physicians (including primary care physicians), and other health care
professionals (collectively, “Health Care Professionals”) for certain uses for
which the Food and Drug Administration had not approved (i.e. “unapproved
uses”); Eli Lilly implemented a marketing strategy to promote Zyprexa to Health
Care Professionals, who treated patients of all ages, for unapproved uses; Eli
Lilly also promoted Zyprexa to Health Care Professionals treating patients in
long term care facilities for unapproved uses; Eli Lilly encouraged Health Care
Professionals to prescribe Zyprexa in higher amounts than the recommended dose;
the promotion of Zyprexa for these unapproved uses violated the Food Drug and
Cosmetic Act, 21 U.S.C. § 331 (a) and 21 U.S.C. § 352(f); Eli Lilly, in
connection with its marketing and promotional efforts for Zyprexa, provided
remuneration and other things of value to Health Care Professionals; and these
unapproved uses were not medically accepted indications for which the United
States and State Medicaid programs provided coverage.    
 
       
 
  As a result of the foregoing alleged conduct, the United States contends that
Eli Lilly knowingly caused false and/or fraudulent claims to be submitted to the
United States and the Medicaid programs and caused TRICARE, the FEHBP, the
Department of Veterans Affairs, the Bureau of Prisons, the Department of
Defense, the Department of Labor, and Public Health Service Entities to purchase
Zyprexa for these unapproved uses.    

     K. The United States also contends that it has certain administrative
claims against Eli Lilly as specified in Paragraphs III.4-6 below, for engaging
in the Covered Conduct.
     L. This Agreement is made in compromise of disputed claims. This Agreement
is neither an admission of facts or liability by Eli Lilly nor a concession by
the United States that its

-4-

--------------------------------------------------------------------------------

 

claims are not well-founded. With the exception of the specific conduct for
which Eli Lilly is pleading guilty as described in the plea agreement filed in
connection with the Federal Criminal action, Eli Lilly expressly denies the
allegations of the United States and the Relators as set forth herein and in the
Civil Actions and denies that it has engaged in any wrongful conduct in
connection with the Covered Conduct. Neither this agreement, its execution, nor
the performance of any obligation under it, including any payment, nor the fact
of settlement, is intended to be, or shall be understood as, an admission of
liability or wrongdoing, or other expression reflecting upon the merits of the
dispute by Eli Lilly.
     M. To avoid the delay, expense, inconvenience, and uncertainty of
protracted litigation of these claims, the Parties mutually desire to reach a
full and final settlement as set forth below.

III.   TERMS AND CONDITIONS

     1. Subject to the terms and procedures set forth below, Eli Lilly agrees to
pay to the United States the sum of Four Hundred Thirty Eight Million, One
Hundred Seventy One Thousand, Five Hundred Forty Three Dollars and Fifty Eight
Cents ($438,171,543.58) plus accrued interest in an amount of 3% per annum from
October 20, 2008 and continuing until and including the day of payment (the
“Federal Settlement Amount”), and — pursuant to the terms of Paragraph III.1.b —
agrees to pay to all of the States and the District of Columbia (which shall be
defined, for purposes of this Agreement, as a State) Three Hundred Sixty One
Million, Eight Hundred Twenty Eight Thousand, Four Hundred Fifty Six Dollars and
Forty Two Cents ($361,828,456.42) plus accrued interest in the amount described
in sub-paragraph III.1.b(ii)

-5-

--------------------------------------------------------------------------------

 

below, of which One Million, Four Hundred Thirty Three Thousand, Six Hundred
Forty Two Dollars and Ninety Six Cents ($1,433,642.96) has already been paid to
the State of Alaska pursuant to a separate settlement agreement. The amount of
Three Hundred Sixty Million, Three Hundred Ninety Four Thousand, Eight Hundred
Thirteen Dollars and Forty Six Cents ($360,394,813.46) shall be defined as the
“Medicaid State Settlement Amount”.
          (a) The Federal Settlement Amount shall be paid by electronic funds
transfer pursuant to written instructions to be provided by the United States.
Eli Lilly agrees to make this electronic funds transfer no later than ten
(10) business days after the date on which the Court accepts Eli Lilly’s guilty
plea in connection with the Federal Criminal Action and imposes the agreed-upon
sentence.
          (b) Eli Lilly shall pay the States according to the following terms:
               (i) No later than ten (10) business days following the date on
which the Court accepts Eli Lilly’s guilty plea in connection with the Federal
Criminal Action and imposes the agreed-upon sentence (the “Account Establishment
Date”), Eli Lilly shall deposit the Medicaid State Settlement Amount plus
accrued interest in the amount of 3% per annum earned on that amount from
October 20, 2008 to the Account Establishment Date into one or more
interest-bearing money market or bank accounts that are held in the name of Eli
Lilly but segregated from other Eli Lilly accounts (the “State Settlement
Accounts”).
               (ii) From the State Settlement Accounts, Eli Lilly shall pay
(through the mechanism described below involving the New York State Attorney
General’s National Global Settlement Account (the “NY State Account”)) to each
State (with the exception of Alaska, with which Eli Lilly has reached a separate
agreement including this matter) that

-6-

--------------------------------------------------------------------------------

 

becomes a Medicaid Participating State (as that term is defined above) within
the time limits established in subparagraph III.1.b(iv) below, that State’s
share of the Medicaid State Settlement Amount (as set forth in a communication
from NAMFCU to Eli Lilly counsel on January 13, 2009) (the “Individual State
Share”) plus accrued interest on that Individual State Share in the amount of 3%
per annum from October 20, 2008 to the Account Establishment Date plus that
State’s pro rata share of interest accrued in the State Settlement Accounts from
the day following the Account Establishment Date until the date that payment is
made to the NY State Account. Eli Lilly shall execute a Medicaid State
Settlement Agreement with any State that executes such an agreement; provided,
however, that Eli Lilly reserves the right not to execute a Medicaid State
Settlement Agreement with any State that is engaged in litigation with Eli Lilly
in a matter relating to Zyprexa. Eli Lilly shall pay the aggregate amount that
it owes to the States that become Medicaid Participating States within 60 days
following the Account Establishment Date to the NY State Account, pursuant to
written wire instructions provided by NAMFCU, on the 70th day following the
Account Establishment Date or within two (2) business days following receipt by
Eli Lilly of the written wire instructions, whichever is later.
          (iii) Eli Lilly may, at its sole discretion, waive any rights that it
has reserved in sub-paragraph III.1.b(ii) with respect to the payment of any of
the Individual State Shares.
          (iv) Except as otherwise provided in this sub-paragraph, absent
Lilly’s consent, no State may become a Medicaid Participating State if it has
not executed a Medicaid State Settlement Agreement within 60 days following the
Account Establishment Date. (A Medicaid Participating State shall be deemed to
have become a Medicaid Participating State on

-7-

--------------------------------------------------------------------------------

 

the date on which it executed a Medicaid State Settlement Agreement.) If, on the
60th day following the Account Establishment Date, Eli Lilly is obligated
pursuant to the terms of sub-paragraph III.1.b(ii) to pay to the NY State
Account an aggregate amount less than the Medicaid State Settlement Amount, Eli
Lilly shall be entitled to retain any such difference, commingle it with any
other corporate funds, and use it for any purpose, and no State shall be
entitled to any portion of that difference pursuant to the terms of this
Agreement. In the event that there are twenty five (25) or more Medicaid
Participating States by the 60th day following the Account Establishment Date,
the deadline for becoming a Medicaid Participating State shall be extended by
30 days, and Eli Lilly’s rights pursuant to this sub-paragraph III.1.b(iv) shall
accrue on the 90th day following the Account Establishment Date. In the event
that the immediately foregoing clause is triggered, Eli Lilly shall pay the
aggregate amount that it owes to the States that become Medicaid Participating
States in the period from 61-90 days following the Account Establishment Date to
the NY State Account, pursuant to written wire instructions provided by NAMFCU,
on the 100th day following the Account Establishment Date or within two (2)
business days following receipt by Eli Lilly of the written wire instructions,
whichever is later.
          (c) Subject to the terms of this paragraph, Eli Lilly shall mail
checks to affected Public Health Service entities the aggregate sum of Seven
Hundred Fifty One Thousand, Five Hundred and Forty Three Dollars and Eighty
Eight Cents ($751,543.88, plus interest accrued thereon at a rate of 3% per
annum from October 20, 2008, continuing until and including the day before
checks are mailed pursuant to this paragraph (the “Public Health Settlement
Amount”). Within 60 days of the date on which the Court accepts Eli Lilly’s
guilty plea in connection with the Federal Criminal Action and imposes the
agreed-upon sentence, Eli

-8-

--------------------------------------------------------------------------------

 

Lilly shall distribute to each affected Public Health Service entity a check in
the amount of its proportionate share of the Public Health Settlement Amount
along with a cover letter referencing this Agreement and providing that, by
cashing the check, the entity is releasing Eli Lilly and its predecessors and
current and former parents, affiliates, divisions, subsidiaries, successors,
transferees, heirs, and assigns, and their current and former directors,
officers and employees, individually and collectively, from liability for the
Covered Conduct.
          (d) Contingent upon the United States receiving the Federal Settlement
Amount from Eli Lilly, the United States agrees to pay, as soon as feasible
after receipt, to Relator Rudolph $78,870,877.84 plus the pro rata share of the
actual accrued interest paid to the United States by Eli Lilly on the amount set
forth in Paragraph III.1.a above (“Relator’s Share”).
          (e) Relators have entered into a separate agreement concerning the
allocation of the Relators’ Share among themselves.
     2. Subject to the exceptions in Paragraph 7 below (concerning excluded
claims), in consideration of the obligations of Eli Lilly in this Agreement,
conditioned upon Eli Lilly’s full payment of the Federal Settlement Amount, and
subject to Paragraph 16 below (concerning bankruptcy proceedings commenced
within 91 days of the Effective Date of this Agreement or any payment made under
this Agreement), the United States (on behalf of itself, its officers, agents,
agencies, and departments) agrees to release Eli Lilly, its predecessors,
current and former parents, affiliates, divisions, subsidiaries, successors,
transferees, heirs, and assigns, and their current and former directors,
officers and employees, individually and collectively, from any civil or
administrative monetary claim the United States has or may have for the Covered
Conduct under the False Claims Act, 31 U.S.C. §§ 3729-3733; the Program Fraud
Civil

-9-

--------------------------------------------------------------------------------

 

Remedies Act, 31 U.S.C. §§ 3801-12; any statutory provision creating a cause of
action for civil damages or civil penalties for which the Civil Division of the
Department of Justice has actual and present authority to assert and compromise
pursuant to 28 C.F.R. Part O, Subpart I, Section 0.45(D) (1999) or the common
law theories of payment by mistake, unjust enrichment, fraud, disgorgement of
illegal profits, and, if applicable, breach of contract.
     Subject to the exceptions in Paragraph 7 below (concerning excluded
claims), in consideration of the obligations of Eli Lilly in this Agreement,
conditioned upon Eli Lilly’s full payment of the Federal Settlement Amount and
compliance with sub-paragraphs III.1.b(i), (ii), and (iv) of this Agreement,
subject to Paragraph 16 below (concerning bankruptcy proceedings commenced
within 91 days of the Effective Date of this Agreement or any payment made under
this Agreement), the United States (on behalf of itself, its officers, agents,
agencies, and departments) agrees to release Eli Lilly, its predecessors and
current and former parents, affiliates, divisions, subsidiaries, successors,
transferees, heirs, and assigns, and their current and former directors,
officers and employees, individually and collectively, from any claim the United
States has or may have for the Covered Conduct under the Civil Monetary
Penalties Law, 42 U.S.C. §1320a-7a.
     3. In consideration of the obligations of Eli Lilly in this Agreement,
conditioned upon Eli Lilly’s full payment of the Federal Settlement Amount and
compliance with sub-paragraphs III.1.b.(i), (ii), and (iv) of this Agreement,
Relators Faltaous, Woodward, Vicente, Rudolph, Rosado, Daywitt, Bradley Lutz,
Wetta, and Lofing, for themselves and for their heirs, successors, transferees,
attorneys, agents, and assigns, agree to dismiss with prejudice any currently
pending claims against Eli Lilly and release Eli Lilly, its predecessors and
current and

-10-

--------------------------------------------------------------------------------

 

former parents, affiliates, divisions, subsidiaries, successors, transferees,
heirs, and assigns, and their current and former directors, officers, employees,
agents, servants, representatives, attorneys, consultants, successors, heirs,
executors, administrators, and assigns, individually and collectively, from all
liability, claims, demands, actions or causes of action whatsoever, known or
unknown, fixed or contingent, in law or in equity, in contract or in tort, under
any federal or state statute or regulation or that they otherwise would have
standing to bring, except that they expressly reserve any claims arising under
the qui tam provisions of the False Claims Act of any State with which Eli Lilly
does not execute a Medicaid State Settlement Agreement pursuant to the terms of
this Agreement.
     4. In consideration of the obligations of Eli Lilly set forth in this
Agreement and the Corporate Integrity Agreement (“CIA”) entered into between
OIG-HHS and Eli Lilly, conditioned on Eli Lilly’s payment in full of the Federal
Settlement Amount and compliance with sub-paragraphs III.1.b(i), (ii), and
(iv) of this Agreement, and subject to Paragraph 16 below (concerning bankruptcy
proceedings commenced within 91 days of the Effective Date of this Agreement or
any payment under this Agreement), the OIG-HHS agrees to release and refrain
from instituting, directing, or maintaining any administrative action seeking
exclusion from the Medicare, Medicaid, and other Federal health care programs
(as defined in 42 U.S.C. § 1320a-7b(f)) against Eli Lilly and Lilly USA, LLC
under 42 U.S.C. § 1320a-7a (Civil Monetary Penalties Law) or 42 U.S.C. §
1320a-7(b)(7) (permissive exclusion for fraud, kickbacks or other prohibited
activities) for the Covered Conduct, except as reserved in Paragraph 7
(concerning excluded claims), below, and as reserved in this Section.

-11-

--------------------------------------------------------------------------------

 

          In consideration of the obligations of Eli Lilly set forth in this
Agreement and the CIA entered into between OIG-HHS and Eli Lilly, conditioned on
Eli Lilly’s payment in full of the Federal Settlement Amount and compliance with
sub-paragraphs III.1.b(i), (ii), and (iv) of this Agreement, and subject to
Paragraph 16 below (concerning bankruptcy proceedings commenced within 91 days
of the Effective Date of this Agreement or any payment made under this
Agreement), the OIG-HHS agrees to release and refrain from instituting,
directing, or maintaining any administrative action seeking exclusion from
Medicare, Medicaid, and other Federal health care programs (as defined in 42
U.S.C. § 1320a-7b(f)) against Eli Lilly under 42 U.S.C. § 1320a-7(b)(l)
(permissive exclusion for conviction relating to fraud) based on the Federal
Criminal Action referenced in Paragraph F, except as reserved in paragraph 7
(concerning excluded claims) below, and as reserved in this Section.
          The OIG-HHS expressly reserves all rights to comply with any statutory
obligations to exclude Eli Lilly from the Medicare, Medicaid, or other Federal
health care programs under 42 U.S.C. § 1320a-7(a) (mandatory exclusion) based
upon the Covered Conduct or the Federal Criminal Action. Nothing in this Section
precludes the OIG-HHS from taking action against entities or persons, or for
conduct and practices, for which claims have been reserved in Paragraph 7,
below.
     5. In consideration of the obligations of Eli Lilly set forth in this
Agreement, conditioned upon Eli Lilly’s full payment of the Federal Settlement
Amount and compliance with sub-paragraphs III.1.b(i), (ii), and (iv) of this
Agreement, and subject to Paragraph 16, below (concerning bankruptcy proceedings
commenced within 91 days of the Effective Date of this Agreement or any payment
under this Agreement), TMA agrees to release and refrain from

-12-

--------------------------------------------------------------------------------

 

instituting, directing, or maintaining any administrative action seeking
exclusion from the TRICARE Program against Eli Lilly, its predecessors and
current and former parents, affiliates, divisions, subsidiaries, successors,
transferees, heirs, and assigns, and their current and former directors,
officers and employees, individually and collectively, under 32 C.F.R. § 199.9
for the Covered Conduct, except as reserved in Paragraph 7 (concerning excluded
claims) below, and as reserved in this Paragraph. TMA expressly reserves its
authority to exclude Eli Lilly under 32 C.F.R. § 199.9(f)(1)(i)(A),
(f)(1)(i)(B), and (f)(1)(iii), based upon the Covered Conduct. Nothing in this
Paragraph precludes TMA or the TRICARE Program from taking action against
entities or persons, or for conduct and practices, for which claims have been
reserved in Paragraph 7, below.
     6. In consideration of the obligations of Eli Lilly set forth in this
Agreement and conditioned upon Eli Lilly’s full payment of the Federal
Settlement Amount and compliance with sub-paragraphs III.1.b(i), (ii), and
(iv) of this Agreement, and subject to Paragraph 16 below (concerning bankruptcy
proceedings commenced within 91 days of the Effective Date of this Agreement or
any payment under this Agreement), OPM agrees to release and refrain from
instituting, directing, or maintaining any administrative action against Eli
Lilly, its predecessors and current and former parents, affiliates, divisions,
subsidiaries, successors, transferees, heirs, and assigns, and their current and
former directors, officers and employees, individually and collectively, under 5
U.S.C. § 8902a(b) or 5 C.F.R. Part 919 for the Covered Conduct, except as
reserved in Paragraph 7 (concerning excluded claims) below, and except if
required by 5 U.S.C. § 8902a(b). Nothing in this Paragraph precludes OPM from
taking action against entities or

-13-

--------------------------------------------------------------------------------

 

persons, or for conduct and practices, for which claims have been reserved in
Paragraph 7, below.
     7. Notwithstanding any term of this Agreement, specifically reserved and
excluded from the scope and terms of this Agreement as to any entity or person
(including Eli Lilly and Relators) are the following claims of the United
States:
          (a) Any criminal, civil, or administrative liability arising under
Title 26, U.S. Code (Internal Revenue Code);
          (b) Any criminal liability except as set forth in the Plea Agreement
resolving the Federal Criminal Action;
          (c) Except as explicitly stated in this Agreement, any administrative
liability, including mandatory exclusion from Federal health care programs;
          (d) Any liability to the United States (or its agencies) for any
conduct other than the Covered Conduct;
          (e) Any liability based upon such obligations as are created by this
Agreement;
          (f) Any liability for express or implied warranty claims or other
claims for defective or deficient products and services, including quality of
goods and services;
          (g) Any liability for personal injury or property damage or for other
consequential damages arising from the Covered Conduct; and
          (h) Any liability for failure to deliver items or services due.
     8. Relators, their heirs, successors, attorneys, agents, and assigns agree
not to object to this Agreement and agree and confirm that this Agreement is
fair, adequate, and reasonable

-14-

--------------------------------------------------------------------------------

 

under all the circumstances, pursuant to 31 U.S.C. § 3730(c)(2)(B). Conditioned
upon Relator Rudolph’s receipt of the Relators’ Share, Relators, for themselves
individually, and for their heirs, successors, agents, and assigns, fully and
finally release, waive, and forever discharge the United States, its officers,
agents, and employees from any claims arising from or relating to 31 U.S.C. §
3730; from any claims arising from the filing of the Civil Actions identified in
Paragraphs II (B) through II (E); from any other claims for a share of the
Settlement Amount; and in full settlement of any claims Relators may have under
this Agreement. This Agreement does not resolve or in any manner affect any
claims the United States has or may have against the Relators arising under
Title 26, U.S. Code (Internal Revenue Code), or any claims arising under this
Agreement.
     9. Eli Lilly waives and shall not assert any defenses it may have to
criminal prosecution or administrative action relating to the Covered Conduct
based in whole or in part on a contention that, under the Double Jeopardy Clause
of the Fifth Amendment of the Constitution, or the Excessive Fines Clause of the
Eighth Amendment of the Constitution, this Agreement bars a remedy sought in
such criminal prosecution or administrative action. Nothing in this paragraph or
any other provision of this Agreement constitutes an agreement by the United
States concerning the characterization of the Settlement Amount for purposes of
the Internal Revenue laws, Title 26 of the United States Code.
     10. Eli Lilly fully and finally releases, waives and discharges the United
States, its agencies, employees, servants, and agents from any claims (including
attorneys’ fees, costs, and expenses of every kind and however denominated) that
Eli Lilly has asserted, could have asserted, or may assert in the future against
the United States, its agencies, employees, servants,

-15-

--------------------------------------------------------------------------------

 

and agents, related to or arising from the Covered Conduct and the United
States’ investigation and prosecution of the Covered Conduct and the Civil
Actions identified in Paragraphs II (B) through (E).
     11. Neither the Federal Settlement Amount nor the Medicaid State Settlement
Amount shall be decreased as a result of the denial of claims for payment now
being withheld from payment by any State or Federal payer, related to the
Covered Conduct; and Eli Lilly shall not resubmit to any State or Federal payer
any previously denied claims, which denials were based on the Covered Conduct,
and shall not appeal or cause the appeal of any such denials of claims.
     12. Eli Lilly agrees to the following:
          (a) Unallowable Costs Defined. All costs (as defined in the Federal
Acquisition Regulation (“FAR”), 48 C.F.R. § 31.205-47 and in Titles XVIII and
XIX of the Social Security Act, 42 U.S.C. §§ 1395-1395hhh and 1396-1396v, and
the regulations and official program directives promulgated thereunder) incurred
by or on behalf of Eli Lilly, its predecessors, parents, divisions,
subsidiaries, or affiliates, and its present or former officers, directors,
employees, and agents in connection with the following shall be “unallowable
costs” on Government contracts: (1) the matters covered by this Agreement;
(2) the United States’ audit and civil and criminal investigation relating to
matters covered by this Agreement; (3) Eli Lilly’s investigation, defense, and
any corrective actions undertaken in response to the United States’ civil and
criminal investigations in connection with the matters covered by this Agreement
(including attorneys’ fees); (4) the negotiation and performance of this
Agreement and the Medicaid State Settlement Agreements and any agreement(s) with
Relators concerning

-16-

--------------------------------------------------------------------------------

 

fees and costs; (5) the payments made to the United States or any State pursuant
to this Agreement or the Medicaid State Settlement Agreements and any payments
that Eli Lilly may make to any qui tam plaintiffs; and (6) the negotiation of
and obligations undertaken pursuant to the CIA to: (a) retain an independent
review organization to perform annual reviews as described in Section III of the
CIA; and (b) prepare and submit reports to OIG-HHS. However, nothing in this
Paragraph affects the status of costs that are not allowable based on any other
authority applicable to Eli Lilly. (All costs described or set forth in this
Paragraph are hereafter, “Unallowable Costs”).
          (b) Future Treatment of Unallowable Costs. If applicable, these
Unallowable Costs shall be separately estimated and accounted for by Eli Lilly
and Eli Lilly shall not charge such Unallowable Costs directly or indirectly to
any contracts with the United States or any State Medicaid program, or seek
payment for such Unallowable Costs through any cost report, cost statement,
information statement, or payment request submitted by Eli Lilly, its
predecessors, parents, divisions, subsidiaries, or affiliates to any government
program.
          (c) Treatment of Unallowable Costs Previously Submitted for Payment.
If applicable, Eli Lilly further agrees that, within 90 days of the Effective
Date of this Agreement, it shall identify to applicable Medicare and TRICARE
fiscal intermediaries, carriers, and/or contractors, and Medicaid, DVA, BOP, and
FEHBP fiscal agents, any Unallowable Costs (as defined in this Paragraph)
included in payments previously sought from the United States, or any State
Medicaid Program, including, but not limited to, payments sought in any cost
reports, cost statements, information reports, or payment requests already
submitted by Eli Lilly, its predecessors, parents, divisions, subsidiaries, or
affiliates and shall request, and agree, that such

-17-

--------------------------------------------------------------------------------

 

cost reports, cost statements, information reports, or payment requests, even if
already settled, be adjusted to account for the effect of the inclusion of the
Unallowable Costs. Eli Lilly agrees that the United States, at a minimum, shall
be entitled to recoup from Eli Lilly any overpayment, plus applicable interest
and penalties, as a result of the inclusion of such Unallowable Costs on
previously-submitted cost reports, information reports, cost statements, or
requests for payment. Any payments due after the adjustments have been made
shall be paid to the United States pursuant to the direction of the Department
of Justice and/or of the affected agencies. The United States reserves its
rights to disagree with any calculations submitted by Eli Lilly, its
predecessors, parents, divisions, subsidiaries or affiliates on the effect of
inclusion of Unallowable Costs on Eli Lilly’s or its predecessors’, parents’,
divisions’, subsidiaries’ or affiliates’ cost reports, cost statements, or
information reports.
          (d) Nothing in this Agreement shall constitute a waiver of the rights
of the United States to examine or re-examine Eli Lilly’s books and records to
determine that no Unallowable Costs have been claimed in accordance with the
provisions of this Paragraph.
     13. This Agreement is intended to be for the benefit of the Parties only.
The Parties do not release any claims against any other person or entity, except
to the extent provided for in Paragraph 14 (Waiver for Beneficiaries paragraph),
below.
     14. Eli Lilly shall not seek payment for any of the claims for
reimbursement covered by this Agreement from any health care beneficiaries or
their parents, sponsors, legally responsible individuals, or third party payors
based upon the claims defined as Covered Conduct.
     15. Eli Lilly warrants that it has reviewed its financial situation and
that it is currently solvent within the meaning of 11 U.S.C. §§ 547(b)(3) and
548(a)(1)(B)(ii)(I), and shall remain

-18-

--------------------------------------------------------------------------------

 

solvent following payment of the Federal Settlement Amount and compliance with
sub-paragraphs III.1.b(i), (ii), and (iv) of this Agreement. Further, the
Parties expressly warrant that, in evaluating whether to execute this Agreement,
they (a) have intended that the mutual promises, covenants, and obligations set
forth herein constitute a contemporaneous exchange for new value given to Eli
Lilly, within the meaning of 11 U.S.C. § 547(c)(1); and (b) have concluded that
these mutual promises, covenants and obligations do, in fact, constitute such a
contemporaneous exchange. Further, the Parties warrant that the mutual promises,
covenants, and obligations set forth herein are intended to and do, in fact,
represent a reasonably equivalent exchange of value that is not intended to
hinder, delay, or defraud any entity that Eli Lilly was or became indebted to on
or after the date of this transfer, within the meaning of 11 U.S.C. § 548(a)(1).
     16. If within 91 days of the Effective Date of this Agreement or of any
payment made under this Agreement, Eli Lilly commences, or a third party
commences, any case, proceeding, or other action under any law relating to
bankruptcy, insolvency, reorganization, or relief of debtors (a) seeking to have
any order for relief of Eli Lilly’s debts, or seeking to adjudicate Eli Lilly as
bankrupt or insolvent; or (b) seeking appointment of a receiver, trustee,
custodian, or other similar official for Eli Lilly or for all or any substantial
part of Eli Lilly’s assets, Eli Lilly agrees as follows, to the extent
consistent with applicable law:
          (a) Eli Lilly’s obligations under this Agreement may not be avoided
pursuant to 11 U.S.C. § 547, and Eli Lilly shall not argue or otherwise take the
position in any such case, proceeding, or action that: (i) Eli Lilly’s
obligations under this Agreement may be avoided under 11 U.S.C. § 547; (ii) Eli
Lilly was insolvent at the time this Agreement was entered into, or

-19-

--------------------------------------------------------------------------------

 

became insolvent as a result of the payment made to the United States; or
(iii) the mutual promises, covenants, and obligations set forth in this
Agreement do not constitute a contemporaneous exchange for new value given to
Eli Lilly.
          (b) In the event that Eli Lilly’s obligations hereunder are avoided
for any reason, including, but not limited to, the exercise of a trustee’s
avoidance powers under the Bankruptcy Code, the United States, at its sole
option, may rescind the releases in this Agreement, and bring any civil and/or
administrative claim, action, or proceeding against Eli Lilly for the claims
that would otherwise be covered by the releases provided in this Agreement. If
the United States chooses to do so, Eli Lilly agrees that, for purposes only of
any case, action, or proceeding referenced in the first clause of this
Paragraph, (i) any such claims, actions or proceedings brought by the United
States (including any proceedings to exclude Eli Lilly from participation in
Medicare, Medicaid, or other federal health care programs) are not subject to an
“automatic stay” pursuant to 11 U.S.C. Section 362(a) as a result of the action,
case or proceeding described in the first clause of this Paragraph, and that Eli
Lilly will not argue or otherwise contend that the United States’ claims,
actions or proceedings are subject to an automatic stay; (ii) that Eli Lilly
will not plead, argue or otherwise raise any defenses under the theories of
statute of limitations, laches, estoppel, or similar theories, to any such civil
or administrative claims, actions, or proceedings which are brought by the
United States within 30 calendar days of written notification to Eli Lilly that
the releases herein have been rescinded pursuant to this Paragraph, except to
the extent such defenses were available before February 21, 2003; and (iii) the
United States and the Medicaid Participating States have valid claims against
Eli Lilly in the aggregate amount of at least $800,000,000 plus applicable
multipliers and

-20-

--------------------------------------------------------------------------------

 

penalties, and they may pursue their claims, inter alia, in the case, action or
proceeding referenced in the first clause of this Paragraph, as well as in any
other case, action, or proceeding; and
          (c) Eli Lilly acknowledges that its agreements in this Paragraph are
provided in exchange for valuable consideration provided in this Agreement.
     17. The United States shall file a Notice of Partial Intervention as to all
Federal Counts in the Civil Actions that pertain to the Covered Conduct, along
with an executed copy of this Agreement. Within five business days after payment
of the Federal Settlement Amount and Eli Lilly’s compliance with sub-paragraph
III.1.b(i) of this Agreement, the United States and the Relators shall file
Stipulations of Dismissal With Prejudice as to all Federal Counts in the Civil
Actions that pertain to the Covered Conduct pursuant to the terms of this
Agreement.
     18. Except as expressly provided to the contrary in this Agreement, each
Party shall bear its own legal and other costs incurred in connection with this
matter, including the preparation and performance of this Agreement.
     19. Eli Lilly represents that this Agreement is freely and voluntarily
entered into without any degree of duress or compulsion whatsoever.
     20. Relators represent that this Agreement is freely and voluntarily
entered into without any degree of duress or compulsion whatsoever.
     21. This Agreement is governed by the laws of the United States. The
Parties agree that the exclusive jurisdiction and venue for any dispute arising
between and among the Parties under this Agreement shall be the United States
District Court for the Eastern District of

-21-

--------------------------------------------------------------------------------

 

Pennsylvania, except that disputes arising under the CIA shall be resolved
exclusively through the dispute resolution provisions set forth in the CIA.
     22. For purposes of construction, this Agreement shall be deemed to have
been drafted by all parties to this Agreement and shall not, therefore, be
construed against any Party for that reason in any subsequent dispute.
     23. This Agreement constitutes the complete agreement between the Parties
with respect to the issues covered by this Agreement. This Agreement may not be
amended except by written consent of the Parties.
     24. The individuals signing this Agreement on behalf of Eli Lilly represent
and warrant that they are authorized by Eli Lilly to execute this Agreement. The
individual(s) signing this Agreement on behalf of Relators represent and warrant
that they are authorized by that Relator to execute this Agreement. The United
States signatories represent that they are signing this Agreement in their
official capacities and that they are authorized to execute this Agreement.
     25. This Agreement may be executed in counterparts, each of which
constitutes an original and all of which constitute one and the same Agreement.
     26. This Agreement is binding on Eli Lilly’s successors, transferees,
heirs, and assigns.
     27. This Agreement is binding on Relators’ successors, transferees, heirs,
attorneys, agents, and assigns.
     28. All Parties consent to the United States’ disclosure of this Agreement,
and information about this Agreement, to the public.

-22-

--------------------------------------------------------------------------------

 

     29. This Agreement is effective on the date of signature of the last
signatory to the Agreement (the “Effective Date”). Facsimiles of signatures
shall constitute acceptable binding signatures for purposes of this Agreement.
     30. Notwithstanding any other provision of this Agreement, if the guilty
plea referenced in Paragraph II.F is not accepted by the Court or the Court does
not impose the agreed upon sentence for whatever reason, this Agreement shall be
null and void at the option of either the United States or Eli Lilly. If either
the United States or Eli Lilly exercises this option, which option shall be
exercised by notifying all Parties, through counsel, in writing within 5
business days of the Court’s decision, the Parties will not object and this
Agreement will be rescinded. If the Agreement is rescinded, Eli Lilly waives any
affirmative defenses based in whole or in part on the running of the statute of
limitations during the period from the Effective Date of this Agreement through
30 days after the effective date of the rescission.

-23-

--------------------------------------------------------------------------------

 

[Page intentionally left blank]

-24-

--------------------------------------------------------------------------------

 

UNITED STATES OF AMERICA

                 
By:
  /s/ Laurie Magid
 
LAURIE MAGID       Dated: 1/14/09    
 
  Acting United States Attorney            
 
  United States Attorney’s Office            
 
  Eastern District of Pennsylvania            
 
               
By:
  /s/ Virginia Gibson       Dated: 1/14/09    
 
               
 
  VIRGINIA GIBSON            
 
  Chief, Civil Division            
 
  United States Attorney’s Office            
 
  Eastern District of Pennsylvania            
 
               
By:
  /s/ Margaret L. Hutchinson       Dated: 1/14/09    
 
               
 
  MARGARET L. HUTCHINSON            
 
  Deputy Chief, Civil Division            
 
  United States Attorney’s Office            
 
  Eastern District of Pennsylvania            
 
               
By:
  /s/ Joseph Trautwein       Dated: 1/14/09    
 
               
 
  JOSEPH TRAUTWEIN            
 
  Assistant U.S. Attorney            
 
  United States Attorney’s Office            
 
  Eastern District of Pennsylvania            

-25-

--------------------------------------------------------------------------------

 

                 
By:
  /s/ Patricia Hanower
 
PATRICIA HANOWER       Dated: January 14, 2009    
 
  Trial Attorney            
 
  Commercial Litigation Branch            
 
  Civil Division            
 
  United States Department of Justice            

-26-

--------------------------------------------------------------------------------

 

                 
By:
  /s/ Gregory E. Demske
 
GREGORY E. DEMSKE       Dated: 1/14/09    
 
  Assistant Inspector General for Legal Affairs            
 
  Office of Counsel to the Inspector General            
 
  Office of Inspector General            
 
  U.S. Department of Health and Human Services            

-27-

--------------------------------------------------------------------------------

 

                 
By:
  /s/ Laurel C. Gillespe
 
LAUREL C. GILLESPE       Dated: 12 Jan 2009    
 
  Deputy General Counsel            
 
  TRICARE Management Activity            
 
  United States Department of Defense On behalf of the TRICARE program          
 

Eli Lilly Settlement Agreement

-28-

--------------------------------------------------------------------------------

 

                 
By:
  /s/ Lorraine E. Dettman
 
LORRAINE E. DETTMAN       Dated: 1/12/09    
 
  Assistant Director            
 
  for Insurance Services Programs            
 
  United States Office of Personnel Management            
 
               
By:
  /s/ J. David Cope
 
J. DAVID COPE       Dated: 1/13/09    
 
  Assistant Inspector General for Legal Affairs            
 
  United States Office of Personnel Management            

On behalf of the Federal Employees Health Benefits Program

-29-

--------------------------------------------------------------------------------

 

ELI LILLY AND COMPANY

                 
By:
  /s/ Robert A. Armitage
 
ROBERT A. ARMITAGE       Dated: 14 Jan 2009    
 
  Senior Vice President and General Counsel            
 
  Eli Lilly and Company            
 
               
By:
  /s/ Paul E. Kalb
 
PAUL E. KALB, M.D.       Dated: 1/14/09    
 
  Sidley Austin LLP            
 
  Counsel for Eli Lilly and Company            
 
               
By:
  /s/ Bradford A. Berenson       Dated: 1/14/09    
 
               
 
  BRADFORD A. BERENSON            
 
  Sidley Austin LLP            
 
  Counsel for Eli Lilly and Company            
 
               
By:
  /s/ Nina M. Gussack       Dated: 1/14/09    
 
               
 
  NINA M. GUSSACK            
 
  Pepper Hamilton LLP            
 
  Counsel for Eli Lilly and Company            
 
               
By:
  /s/ Thomas M. Gallagher       Dated: 1/14/09    
 
               
 
  THOMAS M. GALLAGHER            
 
  Pepper Hamilton LLP            
 
  Counsel for Eli Lilly and Company            

-30-

--------------------------------------------------------------------------------

 

RELATORS

                 
By:
  /s/ Robert Rudolph
 
ROBERT RUDOLPH       Dated: 1/14/09    
 
               
By:
  /s/ Hector Rosado       Dated: 1/14/09    
 
               
 
  HECTOR ROSADO            
 
               
By:
  /s/ Robert Evan Daywitt       Dated: 1/14/09    
 
               
 
  ROBERT EVAN DAYWITT            
 
               
By:
  /s/ Bradley Lutz       Dated: 1/14/09    
 
               
 
  BRADLEY LUTZ            
 
               
By:
  /s/ James Wetta       Dated: 1/14/09    
 
               
 
  JAMES WETTA            
 
               
By:
  /s/ William Lofing       Dated: 1/14/09    
 
               
 
  WILLIAM LOFING            

-31-

--------------------------------------------------------------------------------

 

                 
By:
  /s/ Michael M. Mustokoff
 
MICHAEL M. MUSTOKOFF       Dated: 1/14/09    
 
  Duane Morris, LLP            
 
               
By:
  /s/ Stephen A. Sheller       Dated: 1/14/09    
 
               
 
  STEPHEN A. SHELLER            
 
               
By:
  /s/ Gary M. Farmer       Dated: 1/14/09    
 
               
 
  GARY M. FARMER, JR.            
 
  Rothstein Rosenfeldt Adler            

     (Attorneys for Robert Rudolph, Hector Rosado, Robert Evan Daywitt, Bradley
Lutz, James Wetta and William Lofing)

-32-

--------------------------------------------------------------------------------

 

                 
By:
  /s/ Joseph Faltaous       Dated: 1-14-09    
 
               
 
  JOSEPH FALTAOUS            
 
               
By:
  /s/ Joel Androphy
 
JOEL ANDROPHY       Dated: 1-14-09    
 
  SARAH M. FRAZIER            
 
  Berg & Androphy            
 
               
 
  (Attorneys for Joseph Faltaous)            

-33-

--------------------------------------------------------------------------------

 

                 
By:
  /s/ Steven Woodward
 
STEVEN WOODWARD       Dated: 1/13/09    
 
               
By:
  /s/ Brian P. Kenney       Dated: 1/14/09    
 
               
 
  BRIAN P. KENNEY            
 
  Kenney Egan McCafferty & Young            
 
               
 
  (Attorneys for Steven Woodward)            

-34-

--------------------------------------------------------------------------------

 

                 
By:
  /s/ Jaydeen Vicente
 
JAYDEEN VICENTE       Dated: 01/13/09    
 
               
By:
  /s/ Brian P. Kenney
 
BRIAN P. KENNEY       Dated: 1/14/09    
 
  Kenney Egan McCafferty & Young            
 
               
By:
  /s/ Mark Burton       Dated: 1/14/09    
 
 
 
MARK BURTON            
 
  Hersh & Hersh            
 
               
 
  (Attorneys for Jaydeen Vicente)            

-35-